Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space
Revitalist Lifestyle and Wellness Ltd. (CSE: CALM, OTCQB: RVLWF) has entered into a licensing partnership with Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF) to implement the KARE® protocol for treating Alcohol Use Disorder. Awakn's ketamine-assisted therapy demonstrates significant improvements over current treatment standards, achieving an 86% abstinence rate in post-treatment trials. Revitalist will incur an annual licensing fee and share revenue from services. The U.S. alcohol treatment industry, worth over $30B, faces high relapse rates, which this partnership aims to address.
- Partnership with Awakn aims to improve treatment outcomes for Alcohol Use Disorder.
- Awakn's therapy shows an 86% abstinence rate post-treatment, significantly higher than existing standards.
- Access to proprietary therapeutics and expert training from Awakn for Revitalist providers.
- Expanding operations in a large market with over 14,000 facilities generating $30B in revenue.
- None.
Awakn’s proprietary ketamine-assisted therapy for the treatment of Alcohol Use Disorder was developed and validated in a Phase II a/b trial, with results announced in the
Under the terms of the license agreement Awakn will provide access to the proprietary therapeutics and training by their Subject Matter Experts to the Revitalist providers. Revitalist will pay an annual licensing fee and revenue share for clients seeking services through Revitalist and Awakn’s partnership.
The
Revitalist CEO,
ABOUT
www.AwaknLifeSciences.com | Twitter | LinkedIn | Facebook | www.AwaknClinics.com
ABOUT
Twitter: @RevitalistCorp
Facebook @RevitalistLifestyleandWellnessLtd.
Instagram: @RevitalistCorp
LinkedIn: @RevitalistLifestyleAndWellnessLtd
On Behalf of the Board
Chief Executive Officer
Forward Looking Statements
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Revitalist to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.
Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220815005089/en/
For further information please contact:
Email: Info@Revitalist.com
Tel: (865) 585-8414
Source:
FAQ
What is the significance of the partnership between Revitalist (RVLWF) and Awakn (AWKNF)?
What results did Awakn's therapy achieve in clinical trials?
How does the U.S. alcohol treatment market impact Revitalist (RVLWF)?